Measurement of non‐Coumarin anticoagulants and their effects on tests of Haemostasis: Guidance from the British Committee for Standards in Haematology
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The guideline group was selected to include UK-based medical, scientific and laboratory representatives. Publications known to the writing group were supplemented with additional papers identified by searching MEDLINE/Pubmed using the keywords direct thrombin inhibitors (DTI), direct Xa inhibitors, apixaban, argatroban, bivalirudin, dabigatran, fondaparinux, rivaroxaban, in combination with measurement, monitoring, coagulation assays, haemostasis assays and laboratory tests. The writing group produced the draft guideline, which was subsequently revised by consensus by members of the Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology (BCSH). The BCSH GRADE system was not applied to this guideline as it is inappropriate for laboratory studies. The guideline was then reviewed by a sounding board of c. 50 UK haematologists, the BCSH and British Society for Haematology (BSH) Committee and comments were incorporated where appropriate. The objective of this guideline is to provide healthcare professionals with clear guidance on the clinically important issues regarding the laboratory assessment of currently used non-coumarin anticoagulants and their impact on laboratory tests of haemostasis. A short summary of the effects of rivaroxaban and dabigatran on routine coagulation screens and assessment of anticoagulation intensity on behalf of the BCSH (Baglin et al, 2012) and international recommendations related to measurement of oral direct inhibitors (Baglin et al, 2013) have recently been published. The sections on heparin and low molecular weight heparin (LMWH) represent an update of the previously issued guidance (Baglin et al, 2006). The most common anticoagulants in use in hospitals in the UK are vitamin K antagonists, of which warfarin predominates. Recent BCSH guidelines have addressed warfarin management (Keeling et al, 2011) and this is not discussed in this document. Non-coumarin anticoagulants licensed for use in the UK at the time of writing are listed in Table 1. APTT Anti-Xa, Anti-IIa Drug monitoring aims to use laboratory testing to optimize dosing to increase efficacy and/or safety. Monitoring of anticoagulants, other than warfarin, is primarily indicated for the intravenously administered drugs, such as unfractionated heparin (UFH), danaparoid, argatroban and bivalirudin. Monitoring is not required when anticoagulants are used for prophylaxis, where the anticoagulant effect is predictable and the drugs can be administered at a fixed weight-based dose. The efficacy of this approach has been established by the experience with the subcutaneously administered low molecular dose heparin (LMWH) and fondaparinux. More recently, the oral anticoagulants dabigatran, rivaroxaban and apixaban have been introduced without the intention of routine monitoring. These drugs have been shown in randomized trials to be effective and safe without monitoring (Connolly et al, 2009; Schulman et al, 2009; EINSTEIN Investigators, 2010; Patel et al, 2011). Arguments for and against laboratory monitoring of the new anticoagulants have been published (Bounameux & Reber, 2010; Mismetti & Laporte, 2010). The lack of a need for monitoring is based on the assumed similarity in pharmacokinetic and pharmacodynamic responses between individuals within a relatively wide therapeutic window. It has been estimated that the same dose of direct inhibitors of thrombin and activated factor X (Xa) can have up to 30% difference in thrombin generation inhibition (Al Dieri & Hemker, 2010). Al Dieri and Hemker (2010) also speculated that bleeding would be more likely in high responders and thrombosis more likely in low responders. Clinical trials often exclude patients with impaired renal function, children, the very elderly, those with an increased bleeding risk and those at the extremes of body weight. The lack of a need to monitor demonstrated in the trials may therefore not be applicable to groups excluded from trial entry and the questioning of the extrapolation of overall trial benefit to the individual is not new (Rothwell, 1995). More interest may be focussed on laboratory measurements following an analysis of the association between plasma concentrations and efficacy and safety outcomes, which demonstrated that the risk of ischemic events was inversely related to trough drug levels (Reilly et al, 2014). This study concluded that both ischaemic stroke and bleeding outcomes were correlated with dabigatran plasma concentrations (Reilly et al, 2014). Despite the fact that monitoring is not required for many anticoagulants, it is important that clinical laboratories have the capacity to rapidly measure the concentration of all anticoagulants in the circumstances listed in Table 2, as knowing the concentration of the active drug or its effect may facilitate clinical management decisions. Some published data on the effects of drugs on laboratory tests of haemostasis are based on studies where drug is adde
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Frost, C., Nepal, S., Wang, J., Schuster, A., Byon, W., Boyd, R. A., Yu, Z., Shenker, A., Barrett, Y. C., Mosqueda‐Garcia, R., et al. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12106 · Cited by 286
Martinuzzo, M. E., Barrera, L. H., D 'Adamo, M. A., Otaso, J. C., Gimenez, M. I., & Oyhamburu, J. (2014) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12138 · Cited by 91 · cited 1×
“These recommendations are supported by clinical trial data and laboratory results (Alhenc-Gelas et al, 1995; Kessler et al, 1995; Samama & Poller, 1995; Massicotte et al, 1996; Hunt et al, 1997; Abbate et al, 1998; Crowther et al, 2000; Bombeli et al, 2001).”
Method
Cited by
Gosselin, R., Adcock, D., Bates, S., Douxfils, J., Favaloro, E., Gouin-Thibault, I., Guillermo, C., Kawai, Y., Lindhoff-Last, E., & Kitchen, S. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1627480 · Cited by 392
Self-citationInfluence of DOAC Stop on coagulation assays in samples from patients on rivaroxaban or apixaban
Platton, S., & Hunt, C. (2019) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12950 · Cited by 74
Current Controversies in Lupus Anticoagulant Detection
Moore, G. (2016) · Antibodies · doi:10.3390/antib5040022 · Cited by 36
“Low molecular weight heparins (LMWH) are generally considered to have little or no effect on standard prothrombin time and APTT assays yet dose, LMWH type and reagent variability can generate elevated clotting times [78,79].”
BackgroundDrug therapy in anticoagulation: which drug for which patient?
Millar, C. M., & Laffan, M. A. (2017) · Clinical Medicine · doi:10.7861/clinmedicine.17-3-233 · Cited by 11
Metadata
- Authors
- Kitchen, S., Gray, E., Mackie, I., Baglin, T., Makris, M., & the BCSH committee
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2014-06-14
- Volume
- 166
- Issue
- 6
- Pages
- 830-841
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2085073510
- Cited by
- 167
- References
- 6
- FWCI
- 13.67
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.